David Risinger
Stock Analyst at Leerink Partners
(3.6)
# 282
Out of 5,243 analysts
193
Total ratings
64.77%
Success rate
47.70%
Average return
Main Sectors:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
AbbVie | Upgrades: Outperform | 206 | 171.41 | 20.18% | 7 | Nov 22, 2024 | |
Bristol-Myers Squibb | Upgrades: Outperform | 55 73 | 56.34 | 29.57% | 4 | Nov 12, 2024 | |
Tectonic Therapeutic | Maintains: Outperform | 49 69 | 41.04 | 68.13% | 2 | Nov 11, 2024 | |
Tenax Therapeutics | Initiates Coverage On: Outperform | 16 | 6.37 | 151.18% | 1 | Oct 24, 2024 | |
Regeneron Pharmaceut... | Downgrades: Market Perform | 1175 1077 | 681.92 | 57.94% | 7 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 44 | n/a | n/a | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 106 153 | 85.35 | 79.26% | 2 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | 15 10 | 8.56 | 16.82% | 3 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | 28 2 | 1.9 | 5.26% | 2 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 47 | 15.85 | 196.53% | 1 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | 267 318 | 272.23 | 16.81% | 4 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 6 11 | 15.2 | -27.63% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 410 458 | 726.05 | -36.92% | 16 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | 42 | 54.78 | -23.33% | 3 | Mar 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 374 365 | 422 | -13.51% | 3 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Market Perform | 81 91 | 91.83 | -0.9% | 3 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Market Perform | 49 48 | 26.29 | 82.58% | 14 | Feb 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 194 186 | 147 | 26.53% | 2 | Jan 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 8 10 | 11.16 | -10.39% | 4 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | 88 117 | n/a | n/a | 12 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Market Perform | 7 10 | 12.71 | -21.32% | 2 | Jun 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 35 37 | 15.78 | 134.47% | 2 | Feb 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 162 176 | 121.33 | 45.06% | 3 | Apr 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 18 16 | 11.29 | 41.72% | 1 | Mar 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 53 45 | 23.87 | 88.52% | 7 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 5 7 | n/a | n/a | 8 | Mar 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 22 35 | 7.43 | 371.06% | 4 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 31 41 | 12.03 | 240.81% | 5 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 167 174 | 166.12 | 4.74% | 9 | Nov 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Equal-Weight | 51 | 30.75 | 65.85% | 1 | Jul 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 13 8 | 21.99 | -63.62% | 14 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 23 18 | n/a | n/a | 12 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 97 89 | 98.01 | -9.19% | 8 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 20 16 | 29.48 | -45.73% | 6 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 5 3 | 8.26 | -63.68% | 4 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | 156 | n/a | n/a | 8 | Jan 30, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 14 35 | n/a | n/a | 5 | Aug 17, 2018 |